Skip to content

13F-HR filed by Euclidean Capital LLC

Euclidean Capital LLC filed this 13F-HR for the quarter ended 2024-03-31, filed 2024-05-15, with 13 holding rows worth $779,979,880.

Accession
0001012975-24-000215
Filed
2024-05-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2024

A holdings report, 13 entries on the cover page, a total value of $779,979,880 stated on the cover page (in dollars after the unit check, H1), rows summing to $779,979,880 with VALUE read as dollars as filed, 13F file number 028-20777. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
SPY78462F103SHS974,641$509,805,468dollars as filed
ISHARES TR46429B598MSCI INDIA ETF2,425,144$125,113,179dollars as filed
SPDR GOLD TR78463V107GOLD SHS432,271$88,926,790dollars as filed
ORIC PHARMACEUTICALS INC68622P109COM989,410$13,604,388dollars as filed
FOGHORN THERAPEUTICS INC344174107COMMON STOCK1,573,761$10,559,936dollars as filed
ALECTOR INC014442107COMMON STOCK1,307,858$7,873,305dollars as filed
RAPT THERAPEUTICS INC75382E109COM657,899$5,907,933dollars as filed
23ANDME HOLDING CO90138Q108CLASS A COM10,243,122$5,449,341dollars as filed
TENAYA THERAPEUTICS INC87990A106COM1,015,705$5,312,137dollars as filed
PMV PHARMACEUTICALS INC69353Y103COM2,627,643$4,466,993dollars as filed
NGM BIOPHARMACEUTICALS INC62921N105COM992,168$1,577,547dollars as filed
SURROZEN INC86889P208COMMON STOCK87,696$1,377,704dollars as filed
SURROZEN INC86889P117*W EXP 08/01/203170,833$5,159dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001012975-24-000215this filing2024-05-15acceptance time not in the bulk data set